{"title":"用 ZIF-67 涂布固定表达 Bgps 的大肠杆菌细胞以生产稀有人参皂苷 F1","authors":"","doi":"10.1016/j.bej.2024.109432","DOIUrl":null,"url":null,"abstract":"<div><p>Rare ginsenoside F1 is a potent medicinal component with low natural content. Currently, ginsenoside F1 is primarily produced through enzyme or microbial deglycosylation. Despite its high catalytic efficiency, biocatalyst reuse presents problems. Previously, we obtained ginsenoside hydrolase Bgps using gene mining and expressed it heterologously in <em>E. coli</em>. In this experiment, we immobilized Bgps-containing cells with ZIF-67 and used them for the synthesis of rare ginsenoside F1, thus solving the problem of poor reusability of free cells. Immobilized cells retained more than 80 % of the yield after five batches at 40 °C and pH 9.0 as compared to free cells, and their operational stability was significantly better. After 15 days at 4 °C, the immobilized cells preserved more than 70 % of their initial activity, remained stable, and showed good pH adaptation. This provides a green and sustainable method for the catalytic production of the rare ginsenoside F1 by immobilized cells.</p></div>","PeriodicalId":8766,"journal":{"name":"Biochemical Engineering Journal","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immobilization of Bgps-Expressing Escherichia coli cells coated with ZIF-67 for the production of rare ginsenoside F1\",\"authors\":\"\",\"doi\":\"10.1016/j.bej.2024.109432\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Rare ginsenoside F1 is a potent medicinal component with low natural content. Currently, ginsenoside F1 is primarily produced through enzyme or microbial deglycosylation. Despite its high catalytic efficiency, biocatalyst reuse presents problems. Previously, we obtained ginsenoside hydrolase Bgps using gene mining and expressed it heterologously in <em>E. coli</em>. In this experiment, we immobilized Bgps-containing cells with ZIF-67 and used them for the synthesis of rare ginsenoside F1, thus solving the problem of poor reusability of free cells. Immobilized cells retained more than 80 % of the yield after five batches at 40 °C and pH 9.0 as compared to free cells, and their operational stability was significantly better. After 15 days at 4 °C, the immobilized cells preserved more than 70 % of their initial activity, remained stable, and showed good pH adaptation. This provides a green and sustainable method for the catalytic production of the rare ginsenoside F1 by immobilized cells.</p></div>\",\"PeriodicalId\":8766,\"journal\":{\"name\":\"Biochemical Engineering Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemical Engineering Journal\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1369703X24002195\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical Engineering Journal","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1369703X24002195","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
罕见的人参皂苷 F1 是一种天然含量较低的有效药用成分。目前,人参皂苷 F1 主要通过酶或微生物脱糖法生产。尽管其催化效率高,但生物催化剂的重复使用却存在问题。此前,我们通过基因挖掘获得了人参皂苷水解酶 Bgps,并在大肠杆菌中进行了异源表达。在本实验中,我们用 ZIF-67 固定了含 Bgps 的细胞,并将其用于合成稀有人参皂苷 F1,从而解决了游离细胞重复利用率低的问题。与游离细胞相比,固定化细胞在 40 °C、pH 9.0 条件下经过五次批处理后,产量仍保持在 80% 以上,其操作稳定性也明显更好。在 4 °C 下放置 15 天后,固定化细胞保留了 70% 以上的初始活性,保持稳定,并显示出良好的 pH 适应性。这为固定化细胞催化生产稀有人参皂苷 F1 提供了一种绿色、可持续的方法。
Immobilization of Bgps-Expressing Escherichia coli cells coated with ZIF-67 for the production of rare ginsenoside F1
Rare ginsenoside F1 is a potent medicinal component with low natural content. Currently, ginsenoside F1 is primarily produced through enzyme or microbial deglycosylation. Despite its high catalytic efficiency, biocatalyst reuse presents problems. Previously, we obtained ginsenoside hydrolase Bgps using gene mining and expressed it heterologously in E. coli. In this experiment, we immobilized Bgps-containing cells with ZIF-67 and used them for the synthesis of rare ginsenoside F1, thus solving the problem of poor reusability of free cells. Immobilized cells retained more than 80 % of the yield after five batches at 40 °C and pH 9.0 as compared to free cells, and their operational stability was significantly better. After 15 days at 4 °C, the immobilized cells preserved more than 70 % of their initial activity, remained stable, and showed good pH adaptation. This provides a green and sustainable method for the catalytic production of the rare ginsenoside F1 by immobilized cells.
期刊介绍:
The Biochemical Engineering Journal aims to promote progress in the crucial chemical engineering aspects of the development of biological processes associated with everything from raw materials preparation to product recovery relevant to industries as diverse as medical/healthcare, industrial biotechnology, and environmental biotechnology.
The Journal welcomes full length original research papers, short communications, and review papers* in the following research fields:
Biocatalysis (enzyme or microbial) and biotransformations, including immobilized biocatalyst preparation and kinetics
Biosensors and Biodevices including biofabrication and novel fuel cell development
Bioseparations including scale-up and protein refolding/renaturation
Environmental Bioengineering including bioconversion, bioremediation, and microbial fuel cells
Bioreactor Systems including characterization, optimization and scale-up
Bioresources and Biorefinery Engineering including biomass conversion, biofuels, bioenergy, and optimization
Industrial Biotechnology including specialty chemicals, platform chemicals and neutraceuticals
Biomaterials and Tissue Engineering including bioartificial organs, cell encapsulation, and controlled release
Cell Culture Engineering (plant, animal or insect cells) including viral vectors, monoclonal antibodies, recombinant proteins, vaccines, and secondary metabolites
Cell Therapies and Stem Cells including pluripotent, mesenchymal and hematopoietic stem cells; immunotherapies; tissue-specific differentiation; and cryopreservation
Metabolic Engineering, Systems and Synthetic Biology including OMICS, bioinformatics, in silico biology, and metabolic flux analysis
Protein Engineering including enzyme engineering and directed evolution.